NCT00471367

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a twice a week basis. For Part B, an additional 20 patients will be treated at the maximum dose identified in Part A. AZD4877 is an Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth

Conditions

• Lymphoma
• NHL
• Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	AZD4877	intravenous infusion administered twice a week for 2 weeks

Timeline

• Start date: 2007-04-01
• Completion: 2008-12-01
• First posted: 2007-05-09
• Last updated: 2009-09-24

Locations

3 sites across 1 country: United States